Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
21.27
+0.82 (4.01%)
At close: Feb 21, 2025, 4:00 PM
21.35
+0.08 (0.38%)
After-hours: Feb 21, 2025, 7:49 PM EST
Immunovant Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
207
Market Cap
3.61B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
IMVT News
- 16 days ago - Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - GlobeNewsWire
- 4 weeks ago - Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PRNewsWire
- 2 months ago - Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study - Seeking Alpha
- 2 months ago - FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial - GlobeNewsWire
- 3 months ago - Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - GlobeNewsWire
- 4 months ago - Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - GlobeNewsWire
- 5 months ago - Top 2 Health Care Stocks That May Collapse This Quarter - Benzinga
- 5 months ago - Immunovant Provides Update on Graves' Disease Development Program - GlobeNewsWire